Amrinone
From Wikipedia, the free encyclopedia
 |
|
|
Amrinone
|
|
| Systematic (IUPAC) name | |
| 5-amino-3,4'-bipyridin-6(1H)-one | |
| Identifiers | |
| CAS number | 60719-84-8 |
| ATC code | C01CE01 |
| PubChem | 3698 |
| Chemical data | |
| Formula | C10H9N3O |
| Mol. weight | 187.198 g/mol |
| Pharmacokinetic data | |
| Bioavailability | n/a |
| Protein binding | 10 to 49% |
| Metabolism | Hepatic |
| Half life | 5 to 8 hours |
| Excretion | Renal (63%) and fecal (18%) |
| Therapeutic considerations | |
| Pregnancy cat. |
C(US) |
| Legal status |
℞-only(US) |
| Routes | Intravenous |
Amrinone (INN) or inamrinone, trade name Inocor®, is a pyridine phosphodiesterase inhibitor. It is used in the treatment of congestive heart failure.
| Selective Phosphodiesterase inhibitors (C01CE, G04BE)edit | ||
|---|---|---|
| PDE1: | ||
| PDE2: | ||
| PDE3: |
Amrinone, Bucladesine, Enoximone, Milrinone |
|
| PDE4: | ||
| PDE5: | ||
 |
This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
